These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 37801952)
1. Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder. Li Y; Liu Y; Zhao W; An X; Zhang F; Zhang TX; Liu Y; Du C; Zeng P; Yuan M; Zhang N; Zhang C J Neuroimmunol; 2023 Nov; 384():578218. PubMed ID: 37801952 [TBL] [Abstract][Full Text] [Related]
2. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578 [TBL] [Abstract][Full Text] [Related]
3. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106 [TBL] [Abstract][Full Text] [Related]
4. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C Front Immunol; 2021; 12():647618. PubMed ID: 33796113 [No Abstract] [Full Text] [Related]
5. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502 [TBL] [Abstract][Full Text] [Related]
6. Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Lin TY; Schindler P; Grittner U; Oertel FC; Lu A; Motamedi S; Yadav SK; Duchow AS; Jarius S; Kuhle J; Benkert P; Brandt AU; Bellmann-Strobl J; Schmitz-Hübsch T; Paul F; Ruprecht K; Zimmermann HG Mult Scler Relat Disord; 2022 Nov; 67():104100. PubMed ID: 36049341 [TBL] [Abstract][Full Text] [Related]
7. Combination of serum markers with optical coherence tomography angiography for evaluating neuromyelitis optica spectrum disorders and multiple sclerosis. Liu C; Zhou W; Sun X; Zhang X; Xiao H; Yang H; Lin H; Lu Y; Liu Z; Qiu W; Kermode AG; Yang X; Wang Y Mult Scler Relat Disord; 2024 May; 85():105478. PubMed ID: 38457885 [TBL] [Abstract][Full Text] [Related]
8. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. Aktas O; Hartung HP; Smith MA; Rees WA; Fujihara K; Paul F; Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Cutter G; She D; Gunsior M; Cimbora D; Katz E; Cree BA; J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):757-768. PubMed ID: 37221052 [TBL] [Abstract][Full Text] [Related]
9. Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein. Hyun JW; Kim Y; Kim SY; Lee MY; Kim SH; Kim HJ Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33846219 [TBL] [Abstract][Full Text] [Related]
10. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446 [TBL] [Abstract][Full Text] [Related]
11. Blood sphingolipid as a novel biomarker in patients with neuromyelitis optica spectrum disorder. Kim H; Kim HJ; So J; Kim JY; Jung HJ; Kim S; Seo D; Kim HJ; Song HE; Lim YM; Yoo HJ; Lee EJ Mult Scler Relat Disord; 2024 May; 85():105551. PubMed ID: 38564996 [TBL] [Abstract][Full Text] [Related]
12. Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa. Wang J; Wang J; Xie W; Liu J; Feng J; Wei W; Li M; Wu L; Wang C; Li R Int Immunopharmacol; 2023 Mar; 116():109761. PubMed ID: 36709595 [TBL] [Abstract][Full Text] [Related]
13. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes. Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852 [TBL] [Abstract][Full Text] [Related]
14. High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders. Liu C; Zhao L; Fan P; Ko H; Au C; Ng A; Au L; Wong A; Kermode AG; Mok V; Yan Y; Qiu W; Lau AY J Clin Neurosci; 2021 Jan; 83():108-111. PubMed ID: 33317883 [TBL] [Abstract][Full Text] [Related]
15. Neurofilament light chain and glial fibrillary acid protein levels are elevated in post-mild COVID-19 or asymptomatic SARS-CoV-2 cases. Plantone D; Stufano A; Righi D; Locci S; Iavicoli I; Lovreglio P; De Stefano N Sci Rep; 2024 Mar; 14(1):6429. PubMed ID: 38499607 [TBL] [Abstract][Full Text] [Related]
16. Neurofilament light chain as a biomarker in neuromyelitis optica spectrum disorder: a comprehensive review and integrated analysis with glial fibrillary acidic protein. Kim S; Lee JJ; Park JS; Kang M; Seok HY Neurol Sci; 2024 Mar; 45(3):1255-1261. PubMed ID: 38141119 [TBL] [Abstract][Full Text] [Related]
17. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Aktas O; Smith MA; Rees WA; Bennett JL; She D; Katz E; Cree BAC; Ann Neurol; 2021 May; 89(5):895-910. PubMed ID: 33724534 [TBL] [Abstract][Full Text] [Related]
18. Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis. Loonstra FC; de Ruiter LRJ; Koel-Simmelink MJA; Schoonheim MM; Strijbis EMM; Moraal B; Barkhof F; Uitdehaag BMJ; Teunissen C; Killestein J Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36543540 [TBL] [Abstract][Full Text] [Related]
19. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis. Sainz-Amo R; Rodero Romero A; Monreal E; Chico García JL; Fernández Velasco JI; Villarrubia N; Veiga González JL; Sainz de la Maza S; Rodríguez Jorge F; Masjuan J; Costa-Frossard L; Villar LM Front Immunol; 2024; 15():1454474. PubMed ID: 39224593 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Screening and Monitoring Biomarkers for Brain Metastases. Kim SH; Gwak HS; Lee Y; Park NY; Han M; Kim Y; Kim SY; Kim HJ Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]